Epstein-Barr Virus Infections clinical trials
The registry lists 175 studies for Epstein-Barr Virus Infections across more than 10 countries. 60 are recruiting or about to start. 62 of them are mainly about Epstein-Barr Virus Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 2 narrower conditions too, such as Burkitt Lymphoma: 1,153 studies, 217 open.
Get an email when these change. Save the Epstein-Barr Virus Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Baylor College of Medicine (12) · Beijing Friendship Hospital (10) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · National Cancer Institute (NCI) (7) · Atara Biotherapeutics (5) · AlloVir (4) · ModernaTX, Inc. (3) · Technical University of Munich (3)
What is being tested here
Drugs under test in Epstein-Barr Virus Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Rituximab | 3 | 0 | 9 |
| Acyclovir | 1 | 0 | 5 |
| Tabelecleucel | 1 | 1 | 3 |
| VK-2019 | 1 | 0 | 3 |
| Valacyclovir | 1 | 0 | 3 |
| Methotrexate | 1 | 1 | 3 |
| Zuberitamab | 1 | 0 | 1 |
| Nivolumab | 1 | 0 | 1 |
| Pomalidomide | 1 | 0 | 1 |
| Anti-TCR Vb6/Vb10/IL-2 Antibody Fusion Protein STAR0602 | 1 | 0 | 1 |
Drug classes tested here Antimetabolites 1 open · Immune checkpoint inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Dec 2026Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection · University Hospital, Basel, Switzerland
- Dec 2026Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement · Beijing Friendship Hospital
- Dec 2026EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection · New York Medical College
- Dec 2026Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma · Sun Yat-sen University
- Dec 2026Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma · Hunan Cancer Hospital
- Dec 2026Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection · Chinese PLA General Hospital
- Jan 2027Donor-Derived Viral Specific T-cells (VSTs) · Children's Hospital Medical Center, Cincinnati
- Feb 2027Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors · University Hospital, Basel, Switzerland
- May 2027TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT. · Baylor College of Medicine
- May 2027A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years · Sanofi Pasteur, a Sanofi Company
Who these studies take
Of the 43 Epstein-Barr Virus Infections studies recruiting now, 23 (53%) set no upper age limit and 16 (37%) stop at 75 or younger. 23 (53%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (14%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 19 (44%) | 19 (44%) |
| 18 | 40 (93%) | 40 (93%) |
| 30 | 37 (86%) | 37 (86%) |
| 40 | 36 (84%) | 36 (84%) |
| 50 | 36 (84%) | 36 (84%) |
| 65 | 35 (81%) | 35 (81%) |
| 75 | 30 (70%) | 30 (70%) |
| 85 | 25 (58%) | 25 (58%) |
Across all 175 studies, recruiting or not: 35% stop at 75 or younger and 22% at 65; 49% take children; 0% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting1
- mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young AdultsOct 26, 2026NCT07557602
Newly registered2
- Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young AdultsOct 22, 2026NCT07888088
- 25BT056: Basket Study of Viral Cytotoxic T LymphocytesOct 14, 2026NCT07873970
Studies
Recruiting first, then most recently updated. Showing 50 of 175. Browse all 175 → or search them.
- Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomasRecruitingNCT03258567Phase 21 country
- TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.RecruitingNCT04013802Phase 11 country
- Genetic Studies of Chronic Active Epstein-Barr DiseaseRecruitingNCT000325131 country
- Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV InfectionRecruitingNCT06908096Phase 11 country
- mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young AdultsRecruitingNCT07557602Phase 11 country
- EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV InfectionRecruitingNCT03266653Phase 21 country
- 25BT056: Basket Study of Viral Cytotoxic T LymphocytesNot yet recruitingNCT07873970Early Phase 1
- Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young AdultsNot yet recruitingNCT07888088Phase 11 country
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyRecruitingNCT03394365Phase 39 countries
- Comparative Autoantibody and Immunologic Cell Marker StudyEnrolling by invitationNCT024228751 country
- Epstein-Barr Virus Antibodies in Egyptian Patients With Multiple SclerosisNot yet recruitingNCT07846943
- Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemiaNot yet recruitingNCT07614282Phase 1
- TETRAVI Expanded Access ProgramAvailableNCT07104591
- Third Party Viral Specific T-cells (VSTs)RecruitingNCT02532452Phase 21 country
- Donor-Derived Viral Specific T-cells (VSTs)RecruitingNCT02048332Phase 1/21 country
- A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)RecruitingNCT06789159Phase 11 country
- "Xijiang Project" Screening Cohort for NPCRecruitingNCT067874561 country
- Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus InfectionRecruitingNCT04308278Phase 41 country
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 11 country
- Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive DonorsRecruitingNCT07368153Phase 21 country
- BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCLRecruitingNCT07678229Phase 31 country
- Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative DiseasesRecruitingNCT077270831 country
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsRecruitingNCT05592626Phase 1/24 countries
- R-MVST Cells for Treatment of Viral Infections in Children and Young AdultsRecruitingNCT06926894Phase 11 country
- Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT07693881Not applicable1 country
- Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.RecruitingNCT07685457Not applicable1 country
- Anti-viral T-cell Therapy by Gamma CaptureEnrolling by invitationNCT06027879Phase 1/21 country
- Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.RecruitingNCT07670468Phase 1/21 country
- EBV Specific T-Lymphocytes for Treatment of EBV-Positive LymphomaRecruitingNCT04664179Phase 11 country
- Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal CarcinomaRecruitingNCT06682442Not applicable1 country
- R-MVST Cells for Treatment of Viral InfectionsRecruitingNCT05183490Phase 11 country
- Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCTRecruitingNCT06119256Phase 11 country
- A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of AgeRecruitingNCT07478952Phase 11 country
- Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingNCT07476014Early Phase 1
- Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative DisordersRecruitingNCT07381738Phase 21 country
- Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT07368634Phase 1/21 country
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot StudyRecruitingNCT07294547Not applicable1 country
- Zuberitamab for EBV Infection Post-Allo-HSCTNot yet recruitingNCT07261215Phase 2
- EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07138989Phase 21 country
- Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.Not yet recruitingNCT07133776Phase 1/2
- Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised ImmunityRecruitingNCT06909110Phase 1/21 country
- Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV InfectionsRecruitingNCT04832607Phase 36 countries
- Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk AreasRecruitingNCT06870435Not applicable1 country
- EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ DiseasesNot yet recruitingNCT05688241Phase 1/21 country
- Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV InfectionRecruitingNCT051279801 country
- Multi-Center Registry for ME/CFSRecruitingNCT057780061 country
- Investigating Epstein-Barr Virus Associated ConjunctivitisEnrolling by invitationNCT066893971 country
- Deep Learning-based sbORN Diagnostic ModelRecruitingNCT064633921 country
- Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney AllograftRecruitingNCT04989491Phase 41 country